A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis

OBJECTIVE: The objective of this paper is to assess, in individuals with clinically stable multiple sclerosis (MS), the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of the monoclonal recombinant human antibody IgM22 (rHIgM22). METHODS: Seventy-two adults with stable M...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mult Scler J Exp Transl Clin
Huvudupphovsmän: Eisen, Andrew, Greenberg, Benjamin M, Bowen, James D, Arnold, Douglas L, Caggiano, Anthony O
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2017
Ämnen:
Original Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768281/
https://ncbi.nlm.nih.gov/pubmed/29348926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217317743097
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk